{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Valchlor&page=88", "query": { "intervention": "Valchlor", "page": 88 }, "page_size": 10 }, "pagination": { "page": 88, "page_size": 10, "total_count": 3021, "total_pages": 303, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Valchlor&page=89&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Valchlor&page=87&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T04:37:10.825Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02497404", "title": "Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Erythroblastic, Acute", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "5-Azacytidine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-02-13", "completion_date": "2021-06-17", "has_results": true, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-11-07T04:37:10.825Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02497404" }, { "nct_id": "NCT07038447", "title": "A Study of KITE-363 in Participants With Refractory Autoimmune Diseases", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Lupus Nephritis", "Systemic Sclerosis", "Idiopathic Inflammatory Myopathy" ], "interventions": [ { "name": "KITE-363", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2025-07-02", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-07T04:37:10.825Z", "location_count": 4, "location_summary": "Duarte, California • Stanford, California • Tampa, Florida + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07038447" }, { "nct_id": "NCT05934448", "title": "Pembro Plus CAR T-cell Therapy in R/R in PMBCL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Primary Mediastinal Large B Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma Refractory", "Primary Mediastinal Large B-Cell Lymphoma Recurrent", "Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Lymphodepletion Chemotherapy", "type": "DRUG" }, { "name": "Chimeric Antigen Receptor (CAR) Therapy Infusion", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Jennifer Crombie, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2023-11-15", "completion_date": "2031-06-06", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-11-07T04:37:10.825Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05934448" }, { "nct_id": "NCT00069758", "title": "Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "SDX-105", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cephalon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2003-09", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-11-07T04:37:10.825Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Palm Springs, California • Vista, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palm Springs", "state": "California" }, { "city": "Vista", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069758" }, { "nct_id": "NCT00003211", "title": "Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "3 Years to 20 Years" }, "enrollment_count": 94, "start_date": "1996-10", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2012-11-07", "last_synced_at": "2026-11-07T04:37:10.825Z", "location_count": 2, "location_summary": "Memphis, Tennessee • Houston, Texas", "locations": [ { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003211" }, { "nct_id": "NCT01798004", "title": "Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ganglioneuroblastoma", "Stage 1 Neuroblastoma", "Stage 2 Neuroblastoma", "Stage 2A Neuroblastoma", "Stage 2B Neuroblastoma", "Stage 3 Neuroblastoma", "Stage 4 Neuroblastoma", "Stage 4S Neuroblastoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 150, "start_date": "2013-04-09", "completion_date": "2024-06-30", "has_results": true, "last_update_posted_date": "2024-07-15", "last_synced_at": "2026-11-07T04:37:10.825Z", "location_count": 113, "location_summary": "Birmingham, Alabama • Downey, California • Duarte, California + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01798004" }, { "nct_id": "NCT00409188", "title": "Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tecemotide (L-BLP25)", "type": "BIOLOGICAL" }, { "name": "Single low dose cyclophosphamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1513, "start_date": "2007-01", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-11-07T04:37:10.825Z", "location_count": 49, "location_summary": "Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00409188" }, { "nct_id": "NCT05628883", "title": "Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "Unresectable Melanoma", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "Ocular Melanoma", "Uveal Melanoma", "Iris Melanoma", "Conjunctival Melanoma", "Non-Cutaneous Melanoma" ], "interventions": [ { "name": "TBio-4101", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 17, "start_date": "2022-11-22", "completion_date": "2025-03-06", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-11-07T04:37:10.825Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05628883" }, { "nct_id": "NCT00083551", "title": "UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Thalidomide", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Recombinant GM-CSF", "type": "DRUG" }, { "name": "Interferon-alpha-2b", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 668, "start_date": "1998-08", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-11-23", "last_synced_at": "2026-11-07T04:37:10.825Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083551" }, { "nct_id": "NCT06623630", "title": "Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Ciltacabtagene Autoleucel", "type": "DRUG" }, { "name": "Total body irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2024-12-04", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-11-07T04:37:10.825Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06623630" } ] }